Top of this page
Skip navigation, go straight to the content
A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of €4.9 billion in 2019.
Many companies claim to be patient-driven, but for UCB it is a living reality. In fact, we do not think of people with severe diseases as "patients" but as individuals with lives beyond their disease.